Superior immunogenicity of high-dose quadrivalent inactivated influenza vaccine versus Standard-Dose vaccine in Japanese Adults ≥ 60 years of age: Results from a phase III, randomized clinical trial

Sanchez, Leilani; Nakama, Takahiro; Nagai, Hirokazu; Matsuoka, Osamu; Inoue, Satoshi; Inoue, Takahiro; Shrestha, Anju; Pandey, Aseem; Chang, Lee-Jah; Bruijn, Iris De

doi:10.1016/j.vaccine.2023.02.071

Cited by 4 publications

(2 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, we found no stark difference between elderly individuals (age 65+) receiving high dose vaccines and an adjacent age group (55-64) receiving standard dose Fluzone in any season. Notably, several prior studies found that high dose vaccines elicited higher HAI or led to fewer hospitalizations, [67][68][69] although some studies found little effect. 70 In the UGA studies, the high-dose vaccines may have blunted differences in the response across age groups.…”

Section: Discussionmentioning

confidence: 99%

Leveraging Pre-Vaccination Antibody Titers across Multiple Influenza H3N2 Variants to Forecast the Post-Vaccination Response

Stacey,

Carlock,

Allen

et al. 2024

Preprint

View full text Add to dashboard Cite

Despite decades of research on the influenza virus, we still lack a predictive understanding of how vaccination reshapes each person's antibody response, which impedes efforts to design better vaccines. Here, we combined fifteen prior H3N2 influenza vaccine studies from 1997-2021, collectively containing 20,000 data points, and demonstrate that a person's pre-vaccination antibody titers predicts their post-vaccination response. In addition to hemagglutination inhibition (HAI) titers against the vaccine strain, the most predictive pre-vaccination feature is the HAI against historical influenza variants, with smaller predictive power derived from age, sex, BMI, vaccine dose, the date of vaccination, or geographic location. The resulting model predicted future responses even when the vaccine composition changed or a different inactivated vaccine formulation was used. A pre-vaccination feature ‒ the time between peak HAI across recent variants ‒ distinguished large versus small post-vaccination responses with 73% accuracy. As a further test, four vaccine studies were conducted in 2022-2023 spanning two geographic locations and three influenza vaccine types. These datasets formed a blinded prediction challenge, where the computational team only received the pre-vaccination data yet predicted the post-vaccination responses with 2.2-fold error, comparable to the 2-fold intrinsic error of the experimental assay. This approach paves the way to better utilize current influenza vaccines, especially for individuals who exhibit the weakest responses.

show abstract

Section: Discussionmentioning

confidence: 99%

Leveraging Pre-Vaccination Antibody Titers across Multiple Influenza H3N2 Variants to Forecast the Post-Vaccination Response

Stacey,

Carlock,

Allen

et al. 2024

Preprint

View full text Add to dashboard Cite

show abstract

“…Most studies report higher rates of local and systemic Aes for the hD vaccine when compared to the sD vaccine [55,[63][64][65]. the most frequently reported Aes are as follows: injection-site pain [63,66,67], injection site erythema [67], injection site swelling [67], injection site induration [67], myalgia [63,66], headache [63,66], malaise [66], and shivering [63,66,67]. Most reactions were mild and resolved quickly [63,66].…”

Section: Moving Towards Implementation Of New Improved Influenza Vacc...mentioning

confidence: 99%

Towards better protection of older people against influenza and its complications. Polish recommendations for HD influenza vaccine

Nitsch-Osuch,

Jankowski,

Kokoszka-Paszkot

et al. 2024

fmpcr

View full text Add to dashboard Cite

Annual vaccination is the most effective protection against influenza and its serious complications. it is especially important for people at high risk of severe course of the disease and serious complications: individuals with specific chronic medical conditions, pregnant women, children aged 6-59 months, older people, and healthcare workers. Despite a progressive increase in seasonal vaccine coverage, influenza-related morbidity, mortality, and hospitalization rates remain high and have continued to increase in people aged 65 years and over. standard vaccines against influenza are less efficient in this group due to immunosenescence. consequently, more effective vaccines are needed to prevent influenza and its complications in older adults.

show abstract

A quadrivalent recombinant influenza Hemagglutinin vaccine induced strong protective immune responses in animal models

Feng,

Du,

Chen

et al. 2024

Vaccine

View full text Add to dashboard Cite

Superior immunogenicity of high-dose quadrivalent inactivated influenza vaccine versus Standard-Dose vaccine in Japanese Adults ≥ 60 years of age: Results from a phase III, randomized clinical trial

Cited by 4 publications

References 16 publications

Leveraging Pre-Vaccination Antibody Titers across Multiple Influenza H3N2 Variants to Forecast the Post-Vaccination Response

Leveraging Pre-Vaccination Antibody Titers across Multiple Influenza H3N2 Variants to Forecast the Post-Vaccination Response

Towards better protection of older people against influenza and its complications. Polish recommendations for HD influenza vaccine

A quadrivalent recombinant influenza Hemagglutinin vaccine induced strong protective immune responses in animal models

Contact Info

Product

Resources

About